AbCellera Biologics Inc.

NasdaqGS:ABCL Voorraadrapport

Marktkapitalisatie: US$815.2m

AbCellera Biologics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

AbCellera Biologics heeft een totaal eigen vermogen van $1.1B en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $1.4B en $314.7M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$643.14m
AandelenUS$1.08b
Totaal verplichtingenUS$314.73m
Totaal activaUS$1.39b

Recente financiële gezondheidsupdates

Recent updates

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

AbCellera: A Platform To Pipeline Transition

Oct 14

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $742.9M ) ABCL } overtreffen de korte termijn passiva ( $79.6M ).

Langlopende schulden: De kortetermijnactiva ABCL ( $742.9M ) overtreffen de langetermijnschulden ( $235.2M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ABCL is schuldenvrij.

Schuld verminderen: ABCL heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 56.8% was.

Schuldendekking: ABCL heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: ABCL heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven